Skip to main content
SpringerLink
Log in

Efficiency of Potent Gastric Acid Inhibition

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The evidence regarding the efficiency of potent gastric acid inhibition is exposed after a systematic search and a critical evaluation of its quality, using a specific score. The aim was to review alternative options, in economic terms, especially related with gastro-oesophageal reflux disease. The results show that the superiority of the proton pump inhibitors over the histamine H2 receptor antagonist is clear in moderate and severe oesophagitis and in patients with persistent or severe symptoms. This evidence is clearly related with the intensity of the gastric inhibition. An associated benefit is the improvement of the quality of life obtained with this potent gastric acid inhibition profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Critical Appraisal Skills Programme España (CASPe). 11 preguntas para dar sentido a una evaluación económica [http://www.redcaspe.org/herramientas/lectura/11economica.pdf].

  2. Carballo F. Tratamiento a largo plazo de la ERGE. Análisis coste-efectividad del tratamiento farmacológico (a demanda y continuo) y del tratamiento quirúrgico. Gastroenterol Hepatol 2001; 24 Suppl 2: 54–60

    Google Scholar 

  3. Eggleston A, Wigerinck A, Huijghebaert S, et al. Cost effectiveness of treatment for gastro-esophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998; 42: 13–6

    Article  PubMed  CAS  Google Scholar 

  4. Perras C, Otten N. Pharmaceutical management of gastro-esophageal reflux disease — summary. Technology Overview. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1996.

  5. Goeree R, O’Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive esophagitis. Pharmacoeconomics 1999; 16: 679–97

    Article  PubMed  CAS  Google Scholar 

  6. Hillman AL, Bloom BS, Fendrick AM, et al. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992; 152: 1467–72

    Article  PubMed  CAS  Google Scholar 

  7. Hillman AL. Economic analysis of alternative treatments for persistent gastro-esophageal reflux disease. Scand J Gastroenterol Suppl 1994; 201: 98–102

    Article  PubMed  CAS  Google Scholar 

  8. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997; 92: 2179–87

    PubMed  CAS  Google Scholar 

  9. Stalhammar NO, Carlsson J, Peacock R, et al. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-esophageal reflux disease. Pharmacoeconomics 1999; 16: 483–97

    Article  PubMed  CAS  Google Scholar 

  10. Holzer SS, Juday TR, Joelsson B, et al. Determining the cost of gastroesophageal reflux disease: a decision analytic model. Am J Manage Care 1998; 4: 1450–60

    CAS  Google Scholar 

  11. Sonnenberg A. Cost effectiveness of competing strategies to prevent or treat GORD-related dysphagia. Pharmacoeconomics 2000; 17: 391–401

    Article  PubMed  CAS  Google Scholar 

  12. Stal JM, Gregor JC, Preiksaitis HG, et al. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture. Can J Gastroenterol 1998; 12: 43–9

    PubMed  CAS  Google Scholar 

  13. Gerson LB, Hatton BN, Ryono R, et al. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-esophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 397–406

    Article  PubMed  CAS  Google Scholar 

  14. Kaplan-Machlis B, Spiegler GE, Zodet MW, et al. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med 2000; 9: 624–30

    Article  PubMed  CAS  Google Scholar 

  15. Dean BB, Siddique RM, Yamashita BD, et al. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am J Health Syst Pharm 2001; 58: 1338–46

    PubMed  CAS  Google Scholar 

  16. Meineche-Schmidt V, Juhl HH, Ostergaard JE, et al. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-esophageal reflux symptoms in primary care. Aliment Pharma-col Ther 2004; 19: 907–15

    Article  CAS  Google Scholar 

  17. Raghunath AS, Green JR, Edwards SJ. A review of the clinical and economic impact of using esomeprazole orlansoprazole for the treatment of erosive esophagitis. Clin Ther 2003; 25: 2088–101

    Article  PubMed  CAS  Google Scholar 

  18. Wahlqvist P, Junghard O, Higgins A, et al. Cost effectiveness of proton pump inhibitors in gastro-esophageal reflux disease without esophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Pharmacoeconomics 2002; 20: 267–77

    Article  PubMed  Google Scholar 

  19. Wahlqvist P, Junghard O, Higgins A, et al. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux esophagitis in the UK. Pharmacoeconomics 2002; 20: 279–87

    Article  PubMed  Google Scholar 

  20. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28: 681–7

    CAS  Google Scholar 

  21. Glise H. Quality of life and cost of therapy in reflux disease. Scand J Gastroenterol Suppl 1995; 210: 38–42

    Article  PubMed  CAS  Google Scholar 

  22. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-esophageal reflux disease-like symptoms and endoscopy negative reflux disease [Cochrane Review]. The Cochrane Library, Issue 1. Oxford: Update Software; 2001.

    Google Scholar 

  23. Condra LJ, Morreale AP, Stolley SN, et al. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Manage Care 1999; 5: 631–8

    CAS  Google Scholar 

  24. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54

    Article  PubMed  CAS  Google Scholar 

  25. Sridhar S, Huang J, O’Brien BJ, et al. Clinical economics review: cost-effectiveness of treatment alternatives for gastro-esophageal reflux disease. Aliment Pharmacol Ther 1996; 10: 865–73

    Article  PubMed  CAS  Google Scholar 

  26. Thomson AB, Chiba N, Armstrong D, et al. The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. Can J Gastroenterol 1998; 12: 551–6

    PubMed  CAS  Google Scholar 

  27. Fennerty MB. Medical treatment of gastroesophageal reflux disease in the managed care environment. Semin Gastrointest Dis 1997; 8: 90–9

    PubMed  CAS  Google Scholar 

  28. Hirth RA, Bloom BS, Chernew ME, et al. Patient, physician, and payer perceptions and misperceptions of willingness to pay for diagnostic certainty. Int J Technol Assess Health Care 2000; 16: 35–49

    Article  PubMed  CAS  Google Scholar 

  29. Sadowski D, Champion M, Goeree R, et al. Health economics of gastroesophageal reflux disease. Can J Gastroenterol 1997; 11 Suppl B: 108B–12B

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Section, ‘Morales Meseguer’ University Hospital, Avenida Marqués de los Vélez, s/n, E-30008, Murcia, Spain

    Fernando Carballo Álvarez

Authors
  1. Fernando Carballo Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernando Carballo Álvarez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Álvarez, F.C. Efficiency of Potent Gastric Acid Inhibition. Drugs 65 (Suppl 1), 105–111 (2005). https://doi.org/10.2165/00003495-200565001-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565001-00014

Keywords

Search

Navigation